Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Updates on immunotherapy options for metastatic urothelial carcinoma

Kirollos Hanna • 21 Mar 2018
HOPA 2018
Bladder Cancer Genitourinary Cancer Atezolizumab Pembrolizumab
IMvigor210 KEYNOTE-045

New and exciting developments on urothelial cancer were presented at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO. In this detailed interview, Kirollos Hanna, PharmD, BCOP, BCPS of the University of Minnesota Medical Center, Minneapolis, MN, discusses PD-L1 expression and covers the latest updates on immunotherapy options for metastatic urothelial carcinoma.

More from Kirollos Hanna

HOPA 2018 updates on urothelial carcinoma: what is new?
1:49
HOPA 2018 updates on urothelial carcinoma: what is new?
Kirollos Hanna • 21 Mar 2018
Thoughts on HOPA 2018 and what’s to come: progress in the Oncology Pharmacy community
1:29
Thoughts on HOPA 2018 and what’s to come: progress in the Oncology Pharmacy community
Kirollos Hanna • 21 Mar 2018
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
3:50
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Kirollos Hanna • 21 Mar 2018
Looking towards the future: what is in store for the treatment of bladder cancer?
2:12
Looking towards the future: what is in store for the treatment of bladder cancer?
Kirollos Hanna • 21 Mar 2018

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals